Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Glasdegib in Hepatic Impairment
NCT03627754Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of glasdegib in acute myeloid leukemia (AML) (3 arms), sponsored by Pfizer. Primary endpoints: Area under the plasma concentration-time curve from time 0 to infinity and Maximum observed plasma concentration at Day 1. Started Nov 2018; status: completed.
02
Drugs
glasdegib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03627754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03627754.